What Does the Second Circuit’s Recent Decision in United States v. Caronia Not Say?

February 13, 2013 | Health Services

Geoffrey (Jeff) Kaiser is a frequent speaker on the subject of off-label marketing and has published an article on the Second Circuit’s decision in United States v. Caronia, of which Jeff has a unique insider’s perspective, having handled the government’s investigation as Chief of Health Care Fraud Prosecutions in the United States Attorney’s Office for the Eastern District of New York.  Click here to read Jeff’s article entitled, What Does the Second Circuit’s Recent Decisions in United States v. Caronia Not Say?, previously published in the Food and Drug Policy Forum, in which Jeff discusses the impact of the Caronia decision on: (1) the permitted promotional activities of pharmaceutical companies; (2)  the continued viability of the Park doctrine in prosecuting misbranding violations; and (3) the exercise of prosecutorial discretion moving forward.

Related Publications

Legal updates and news delivered to your inbox